ICAM1 and neurodegenerative disease: Therefore, this report suggests that using NF-κB -specific anti-inflammatory agents or blocking the function of the Fg receptors ICAM-1 and PrPC should be considered as candidates for the treatment of the Fg-induced neuroinflammatory effects that accompany neurodegenerative diseases and in particular TBI, which is associated with chronic inflammation, deposition of Fg in the brain parenchyma, and increased neurodegeneration resulting in memory reduction.